Ultragenyx Pharma (RARE) Misses Q3 EPS by 1c

Ultragenyx Pharma (NASDAQ: RARE) reported Q3 EPS of ($1.87), $0.01 worse than the analyst estimate of ($1.86). Revenue for the quarter came in at $198 thousand versus the consensus estimate of $20 thousand.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• SailPoint Technologies Holdings (SAIL) Tops Q2 EPS by 1c, Offers Guidance
• McGraw Hill (MH) Tops Q1 EPS by 15c, Beats on Revenue; Offers FY26 Revenue Guidance